Despite global trade tensions and shifting narratives, analysts say long-term signals still support optimism for bitcoin
Bitcoin is rapidly approaching the $100,000 mark after a turbulent week that wiped billions from the digital asset market. Following last weekend’s sell-off, the world’s largest cryptocurrency has fallen nearly 7% since Monday, according to data from Messari, erasing most of its 2025 gains and weakening the once-dominant “safe-haven” narrative.
At around $107,000, bitcoin’s year-to-date return has slipped to just 14%, now roughly in line with the S&P 500. Companies tied to bitcoin have mirrored the downturn: shares of MicroStrategy (MSTR), Coinbase (COIN), and Circle (CRCL) are all down more than 5% over the past week. The recent pullback was triggered largely by renewed trade tensions between the United States and China, sparking a broader risk-off sentiment across markets.
The downturn has also exposed cracks in bitcoin’s perceived role as “digital gold.” While gold has surged to record highs in recent weeks, investors seeking safety have shifted away from crypto. “Gold is the new bitcoin,” wrote Ed Yardeni of Yardeni Research, highlighting a shift in investor psychology.
Yet despite short-term volatility, many analysts say the long-term outlook remains constructive. Ben Cowen of Into the Cryptoverse notes bitcoin is still holding above its 50-week moving average, currently near $100,000, a level he views as a crucial support. He predicts another potential rally before a broader market correction in 2026.
Institutional sentiment also appears resilient. Recent reports from Ark Invest and Fidelity highlight strengthening on-chain metrics, rising corporate bitcoin adoption, and growing institutional inflows. Matt Hougan of Bitwise Asset Management added that recent market stress revealed crypto’s growing maturity: “No major players collapsed, and blockchains held firm.”
While uncertainty remains, crypto strategists agree—bitcoin may be jittery now, but its long-term fundamentals are still intact.
You might like this article:Praxis Announces Breakthrough Phase 3 Results for Ulixacaltamide in Essential Tremor Treatment
